PTGS2 and gastric adenocarcinoma: Specifically, GEPIA showed PTGS2 downregulation in bladder, breast, colon, lung, and prostate cancers and upregulation in oesophageal carcinoma, stomach adenocarcinoma, and head and neck squamous cell carcinoma.